<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0705233595
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MEKTOVI
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BINIMETINIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        84
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        10134.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Almac Pharma Services Limited" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Almac Pharma Services Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Europe MA EEIG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XE41
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MEKTOVI is an anti-cancer medicine that contains the active substance binimetinib. It is used in adults in combination with another medicine containing encorafenib to treat a type of skin cancer called melanoma when it has</p><ul><li>a particular change (mutation) in a gene responsible for producing a protein called BRAF, and</li><li>spread to other parts of the body or cannot be removed by surgery.</li></ul><p>&nbsp;</p><p>MEKTOVI is a prescription medicine used in combination with a medicine called encorafenib to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC):</p><ul><li>that has spread to other parts of the body, and</li><li>that has a certain type of abnormal &ldquo;BRAF&rdquo; gene</li></ul><p>&nbsp;</p><p>Mutations in the BRAF gene can produce proteins that cause the melanoma to grow. MEKTOVI targets another protein called &ldquo;MEK&rdquo; that stimulates cancer cell growth. When MEKTOVI is used in combination with encorafenib (which targets the changed &ldquo;BRAF&rdquo; protein), the combination slows down or stops the growth of your cancer.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Before starting treatment your doctor will check for BRAF mutation.</p><p>&nbsp;</p><p>As MEKTOVI is to be used in combination with encorafenib, read the encorafenib leaflet carefully as well as this leaflet.&nbsp;</p><p>&nbsp;</p><p><strong>Do not take MEKTOVI</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; if you are allergic to binimetinib or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor, pharmacist or nurse<strong> </strong>before taking<strong> </strong>MEKTOVI about all of your medical conditions, particularly if you have any of the following:&nbsp;</p><ul><li>heart problems</li><li>bleeding problems or if you are taking medicines that may cause bleeding</li><li>eye problems including glaucoma or increased pressure in your eyes</li><li>muscle problems</li><li>high blood pressure (hypertension)</li><li>blood clots</li><li>lung or breathing problems</li><li>liver or kidney problems</li></ul><p>&nbsp;</p><p>Tell your doctor if you have ever had blockage in the vein carrying blood away from the eye (retinal vein occlusion), as MEKTOVI is not recommended in such cases.</p><p>&nbsp;</p><p>Tell your doctor if you have had a different type of cancer than melanoma, as binimetinib when taken with encorafenib may worsen certain other types of cancers.</p><p>&nbsp;</p><p>Tell your doctor, pharmacist or nurse immediately if you get the following while you are taking this medicine:</p><p>&nbsp;</p><ul><li><strong>Heart problems: </strong>MEKTOVI, when taken with encorafenib can make your heart work less well, or make existing heart problems worse. Your doctor will check that your heart is working properly before and during your treatment with this medicine. Talk to your doctor immediately if you have any symptoms of heart problems such as feeling dizzy, tired, lightheaded, if you have shortness of breath, if you feel like your heart is pounding, racing, beating irregularly or if you have swelling in the legs (ankles and feet).</li></ul><p>&nbsp;</p><ul><li><strong>Bleeding problems:</strong> MEKTOVI, when taken with encorafenib may cause serious bleeding problems in brain or stomach. Talk to your doctor immediately if you have any symptoms of bleeding problems such as coughing up of blood, blood clots, vomit containing blood or that looks like &ldquo;coffee grounds&rdquo;, red or black stools that look like tar, passing blood in the urine, stomach (abdominal) pain, unusual vaginal bleeding. Also tell your doctor if you have headache, dizziness or weakness.</li></ul><p>&nbsp;</p><ul><li><strong>Eye problems:</strong><strong> </strong>MEKTOVI, when taken with encorafenib can cause serious eye problems. Talk to your doctor immediately if you get blurred vision, loss of vision or other vision changes (such as coloured dots in your vision), halo (seeing blurred outline around objects), eye pain, swelling, or redness. Your doctor will examine your eyes for any problems with your sight while you are taking Mektovi. &nbsp;</li></ul><p>&nbsp;</p><ul><li><strong>Muscle problems:</strong><strong> </strong>MEKTOVI, when taken with encorafenib can cause breakdown of muscle (rhabdomyolysis). Your doctor will run blood tests to check level of an enzyme called creatine phosphokinase (CPK) that can be a sign of muscle problems before and during treatment. As a precaution, drink plenty of fluids during treatment. Talk to your doctor immediately if you get muscle pain, cramps, stiffness, spasm, dark reddish urine.</li></ul><p>&nbsp;</p><ul><li><strong>High blood pressure:</strong> MEKTOVI, when taken with encorafenib can raise blood pressure. Your doctor or nurse will check your blood pressure before and during treatment with MEKTOVI. Talk to your doctor immediately if you get severe headache, feel dizzy, lightheaded or if your blood pressure measured on a home blood pressure device is much higher than usual.</li></ul><p>&nbsp;</p><ul><li><strong>Blood clots:</strong> MEKTOVI, when taken with encorafenib can cause blood clots in your arms or legs, and if a clot travels to your lungs it could lead to death. Talk to your doctor immediately if you get chest pain, sudden shortness of breath, trouble breathing, pain in your legs with or without swelling, swelling in your arms and legs, or a cool, pale arm or leg. If necessary, your doctor may interrupt your treatment or stop it altogether.</li></ul><p>&nbsp;</p><ul><li><strong>Lung or breathing problems:</strong> MEKTOKI, when taken with encorafenib may cause lung or breathing problems including inflammation of the lungs (pneumonitis or interstitial lung disease); signs and symptoms can include: cough, shortness of breath or fatigue. If necessary, your doctor may interrupt your treatment or stop it altogether.</li></ul><p>&nbsp;</p><ul><li><strong>Skin changes:</strong> MEKTOVI, when taken with encorafenib, may cause other types of skin cancer such as cutaneous squamous cell carcinoma or basal cell carcinoma. Your doctor will check your skin before initiation of treatment, every 2 months during treatment, and for up to 6&nbsp;months after you stop taking these medicines to look for any new skin cancer. Tell your doctor immediately if you detect any skin changes during and after the treatment<strong> </strong>including:<strong> </strong>new wart, skin sore or reddish bump that bleeds or does not heal, or a change in size or colour of a mole.</li></ul><p>Additionally, your doctor needs to check for squamous cell carcinoma on your head, neck, mouth and lymph glands, and you will have CT scans regularly. This is a precaution in case a squamous cell carcinoma develops inside your body. Genital examinations (for women) and anal examinations are also recommended before the initiation and at the end of your treatment.</p><p>&nbsp;</p><ul><li><strong>Liver problems:</strong> MEKTOVI, when taken with encorafenib can cause abnormal blood tests related to your liver (raised levels of liver enzymes). Your doctor will run blood tests to check your liver before and during treatment. Talk to your doctor if you have any signs and symptoms of liver problem such as yellowing of skin and eyes, dark or brown (tea-coloured) urine, nausea or vomiting, tiredness, bruising, bleeding and loss of appetite.</li></ul><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p>MEKTOVI is not recommended for children and adolescents under 18 years of age. This medicine has not been studied in this age group.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and MEKTOVI</strong></p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.</p><p>Some medicines may affect how MEKTOVI works, or make it more likely that you will have side effects. In particular, tell your doctor if you are taking anything in this list or any other medicines:</p><ul><li>some medicines to treat bacterial infections such as rifampicin, ciprofloxacin</li><li>some medicines typically used to treat epilepsy such as phenobarbital, phenytoin, carbamazepine</li><li>some medicines to treat HIV such as indinavir, atazanavir</li><li>a medicine for carcinoma treatment called sorafenib</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an herbal treatment for depression: St. John&rsquo;s wort</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicine used to treat depression such as duloxetine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicine typically used to treat high cholesterol such as pravastatin</p><ul><li>a medicine used to treat breathing problems, theophylline.</li></ul><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast-feeding </strong></p><p>Pregnancy</p><p>MEKTOVI is not recommended during pregnancy. It may cause permanent harm or birth defects to an unborn baby.</p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>If you are a woman who could become pregnant, you must use reliable contraception<strong> </strong>while you are taking MEKTOVI, and you must continue to use reliable contraception at least 30 days after taking your last dose. Contact your doctor straightaway if you become pregnant while taking MEKTOVI.</p><p>&nbsp;</p><p>Breast-feeding</p><p>MEKTOVI is not recommended while breast-feeding.<strong> </strong>It is not known if MEKTOVI passes into breast milk. If you are breast-feeding, or planning to breast-feed, ask your doctor for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>MEKTOVI can affect your ability to drive or use machines. Avoid driving or using machines if you have any problems with your vision or have any other side effects that can affect your ability to drive or use machines (see section&nbsp;4), while taking MEKTOVI. Talk to your doctor if you are not sure you can drive.</p><p>&nbsp;</p><p><strong>MEKTOVI contains lactose</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How much to take </strong></p><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>The recommended dose of MEKTOVI is 45&nbsp;mg (3 tablets of 15&nbsp;mg) twice daily, taken about 12&nbsp;hours apart<strong> (</strong>corresponding to a daily dose of 90&nbsp;mg). You will also receive treatment with another medicine, encorafenib.</p><p>&nbsp;</p><p>If you get serious side effects (such as heart, eye or skin problems) your doctor may lower the dose or stop treatment temporarily or permanently.</p><p>&nbsp;</p><p><strong>How to take MEKTOVI</strong></p><p>MEKTOVI can be taken with food or between meals.</p><p>&nbsp;</p><p><strong>If you are sick </strong></p><p>If you vomit at any time after taking MEKTOVI, do not take an additional dose. Take the next dose as scheduled.</p><p>&nbsp;</p><p><strong>If you take more MEKTOVI than you should</strong></p><p>If you take more tablets than you should, contact your doctor, pharmacist or nurse straightaway.<strong> </strong>If possible, show them this leaflet and the medicine package.</p><p>&nbsp;</p><p><strong>If you forget to take MEKTOVI</strong></p><p>If you miss a dose of MEKTOVI, take it as soon as you remember. However, if the missed dose is more than 6 hours late, skip that dose and take your next dose at the usual time. Then continue taking your tablets at regular times as usual.</p><p>Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking MEKTOVI</strong></p><p>It is important to take MEKTOVI for as long as your doctor prescribes it. Do not stop taking this medicine unless your doctor tells you to.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p><strong>&nbsp;</strong></p><p><strong>MEKTOVI may cause serious side effects. Tell your doctor immediately </strong>if you have any of the following serious side effects, either for the first time or if they get worse (see also section&nbsp;2).</p><p>&nbsp;</p><p><strong>Heart problems:</strong><strong> </strong>MEKTOVI can affect how well your heart works (left ventricular ejection fraction decrease); signs and symptoms can include:</p><ul><li>feeling dizzy, tired or lightheaded</li></ul><ul><li>shortness of breath</li><li>feeling like your heart is pounding, racing or beating irregularly</li><li>swelling in the legs (ankles and feet)</li></ul><p>&nbsp;</p><p><strong>High blood pressure:</strong><strong> </strong>MEKTOVI can increase blood pressure. Tell your doctor immediately if you get<strong> </strong>severe headache, feel dizzy or lightheaded or if your blood pressure measured on a home blood pressure device is much higher than usual.</p><p>&nbsp;</p><p><strong>Blood clots:</strong><strong> </strong>MEKTOVI may cause blood clots (venous thromboembolism including pulmonary embolism); signs and symptoms can include:</p><ul><li>chest pain</li><li>sudden shortness of breath or trouble breathing</li><li>pain in your legs with or without swelling</li><li>swelling in your arms and legs</li><li>a cool, pale arm or leg</li></ul><p>&nbsp;</p><p><strong>Eye problems:</strong> MEKTOVI can cause fluid to leak under the retina in the eye, leading to detachment of different layers in the eye (retinal pigment epithelial detachment) which could lead to:</p><ul><li>blurred vision, loss of vision, or other vision changes (such as coloured dots in your vision)</li><li>halo (seeing blurred outline around objects)</li><li>eye pain, swelling or redness</li></ul><p>&nbsp;</p><p><strong>Muscle problems:</strong> MEKTOVI can cause breakdown of muscles (rhabdomyolysis) which can lead to kidney damage and can be fatal; signs and symptoms can include:</p><ul><li>muscle pain, cramps, stiffness or spasm</li><li>dark reddish urine</li></ul><p>&nbsp;</p><p><strong>Bleeding problems:</strong> MEKTOVI can cause serious bleeding problems. Tell your doctor right away<strong> </strong>if you have any unusual bleeding or signs of bleeding, including:<strong> </strong></p><ul><li>headaches, dizziness or weakness</li><li>coughing up of blood or blood clots</li><li>vomit containing blood or that looks like &ldquo;coffee grounds&rdquo;</li><li>red or black stools that look like tar</li><li>passing blood in the urine</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach (abdominal) pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual vaginal bleeding</p><p>&nbsp;</p><p><strong>Other skin cancers:</strong> When MEKTOVI is taken with encorafenib, the patient may develop different types of skin cancer such as cutaneous squamous cell carcinoma. Usually, these skin cancers (see also section 2) are confined to a small area and can be removed with surgery and treatment with MEKTOVI (and encorafenib) can continue without interruption.</p><p>&nbsp;</p><p><strong>Other side effects when MEKTOVI and encorafenib are taken together:</strong></p><p>Besides the serious side effects mentioned above, people taking MEKTOVI and encorafenib together may also get the following side effects.</p><p><strong>&nbsp;</strong></p><p><strong>The most common side effects of MEKTOVI when taken with encorafenib, for melanoma include:</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatigue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach-area (abdominal) pain</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>The most common side effects of MEKTOVI when taken with encorafenib for NSCLC include:</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:606px"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatigue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle or joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach-area (abdominal) pain</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision, loss of vision, or other vision changes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To Report</strong><strong> side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><ul><li>SFDA Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa</li></ul></td></tr></tbody></table><p><u>&nbsp;</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30&deg;C.</p><p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the blister and the carton after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is binimetinib. Each film‑coated tablet contains 15&nbsp;mg of binimetinib.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tablet core: lactose monohydrate, cellulose microcrystalline (E460i), silica colloidal anhydrous (E551), croscarmellose sodium (E468) and magnesium stearate (E470b). See section 2 &ldquo;MEKTOVI contains lactose&rdquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tablet film‑coat: polyvinyl alcohol (E1203), macrogol 3350 (E1521), titanium dioxide (E171), talc (E533b), iron oxide yellow (E172) and iron oxide black (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	MEKTOVI film-coated tablets are yellow to dark yellow, unscored biconvex, oval film-coated tablets debossed with a stylized “A” on one side and “15” on the other side. 
	
	MEKTOVI is available in pack of 84 tablets (7 blisters of 12 tablets each). 
	


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Pfizer Europe MA EEIG &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Boulevard de la Plain 17, 1050, Bruxelles, Belgium</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>ALMAC Pharma Services Limited&nbsp;<br />Portadown, Craigavon, United Kingdon<br /><br /><strong>Packaging &amp; Release by</strong></p><p>PIERRE FABRE MEDICAMENT PRODUCTION</p><p>Site Progipharm, GIEN, France</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                October 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ميكتوفي هو دواء مضاد للسرطان يحتوي على المادة الفعالة بينيميتينيب. يتم استخدام ميكتوفي في البالغين مع دواء آخر يحتوي على إنكورافينيب لعلاج نوع من سرطان الجلد يسمى الورم الميلانيني عند</p><ul><li dir="RTL">وجود تغير (طفرة) معين في الجين المسؤول عن إنتاج بروتين يسمى BRAF،</li><li dir="RTL">وانتشار الورم إلى أجزاء أخرى من الجسم، أو في حالة عدم القدرة على إزالته جراحيًا.</li></ul><p>&nbsp;</p><p dir="RTL">ميكتوفي هو دواء يُصرف بوصفة طبية ويُستخدم مع دواء يسمى إنكورافينيب لعلاج البالغين المصابين بنوع من سرطان الرئة يسمى سرطان الرئة ذو الخلايا غير الصغيرة (NSCLC):</p><ul><li dir="RTL">والذي انتشر إلى أجزاء أخرى من الجسم،</li><li dir="RTL">ولديه نوع معين غير طبيعي من الجين المسؤول عن إنتاج بروتين &quot;BRAF&quot;</li></ul><p>&nbsp;</p><p dir="RTL">يمكن أن تؤدي الطفرات في جين BRAF إلى إنتاج بروتينات تتسبب في نمو الأورام الميلانينية. يستهدف ميكتوفي بروتينًا آخر يسمى &quot;MEK&quot; يحفز نمو الخلايا السرطانية. عند استخدام ميكتوفي مع إنكورافينيب (الذي يستهدف بروتين &quot;BRAF&quot; المتغير)، يؤدي الجمع بينهما إلى إبطاء نمو السرطان الذي تعاني منه أو إيقافه.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;قبل بدء العلاج، سيفحصك طبيبك للتحقق من وجود طفرة BRAF.</p><p>&nbsp;</p><p dir="RTL">&nbsp;نظرًا لاستخدام ميكتوفي مع إنكورافينيب، اقرأ نشرة إنكورافينيب بعناية وكذلك هذه النشرة.&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>موانع استعمال ميكتوفي</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; &nbsp;إذا كنت تعاني من حساسية تجاه بينيميتينيب أو أي مكون آخر من مكونات هذا الدواء (المدرجة في القسم ٦).</p><p>&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال ميكتوفي</strong></p><p dir="RTL">&nbsp;تحدث مع طبيبك أو الصيدلي أو الممرضة قبل تناول ميكتوفي بشأن جميع حالاتك الطبية، خاصة إذا كنت تعاني من أي مما يلي:&nbsp;</p><ul><li dir="RTL">مشكلات في القلب</li><li dir="RTL">مشكلات نزيف أو إذا كنت تتناول أدوية قد تسبب النزيف</li><li dir="RTL">&nbsp;مشكلات في العين بما في ذلك الزرق أو ارتفاع الضغط داخل عينيك</li><li dir="RTL">مشكلات عضلية</li><li dir="RTL">ضغط الدم المرتفع (الضغط المرتفع)</li><li dir="RTL">الجلطات الدموية</li><li dir="RTL">مشكلات في الرئة أو التنفس</li><li dir="RTL">مشكلات في الكبد أو الكلى</li></ul><p>&nbsp;</p><p dir="RTL">أخبر طبيبك إذا سبق أن أُصبت بانسداد في الوريد الذي يحمل الدم من العين (انسداد الوريد الشبكي)، حيث يوصى بعدم استخدام ميكتوفي في مثل هذه الحالات.</p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت مصابًا بنوع مختلف من السرطان بخلاف الورم الميلانيني، نظرًا لأن تناول بينيميتينيب مع إنكورافينيب قد يؤدي إلى تفاقم حالة بعض آخر من أنواع السرطانات.</p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرضة فورًا إذا أصبت بما يلي خلال فترة تناول هذا الدواء:</p><p>&nbsp;</p><ul><li dir="RTL"><strong>مشكلات في القلب:</strong> يمكن أن يؤدي تناول ميكتوفي مع إنكورافينيب إلى عمل قلبك بكفاءة أقل أو التسبب في تفاقم حالة مشكلات القلب القائمة. سيتحقق طبيبك من أن قلبك يعمل بشكل سليم قبل وأثناء علاجك بهذا الدواء. تحدث إلى طبيبك على الفور إذا كان لديك أي أعراض للإصابة بمشكلات في القلب مثل الشعور بالدوار، أو التعب، أو الدوخة، أو إذا كنت تعاني من ضيق التنفس، أو إذا شعرت بأن قلبك يخفق بشدة أو ضرباته متسارعة أو ينبض بشكل غير منتظم، أو إذا كنت تعاني من تورم في الساقين (الكاحلين والقدمين).</li></ul><p>&nbsp;</p><ul><li dir="RTL"><strong>مشكلات نزيف:</strong> قد يسبب ميكتوفي عند تناوله مع إنكورافينيب مشكلات نزيف خطيرة في الدماغ أو المعدة. تحدث إلى طبيبك على الفور إذا كان لديك أي أعراض لمشكلات نزيف مثل السعال المصحوب بخروج الدم، جلطات الدم، القيء الذي يحتوي على دم أو الذي يشبه &quot;ثفل القهوة&quot;، البراز الأحمر أو الأسود الذي يشبه القطران، خروج دم في البول، آلام المعدة (البطن)، النزيف المهبلي غير المعتاد. أخبر طبيبك أيضًا إذا كنت تعاني من الصداع، أو الدوار، أو الضعف.</li></ul><p>&nbsp;</p><ul><li dir="RTL"><strong>مشكلات في العين:</strong> يمكن أن يسبب ميكتوفي عند تناوله مع إنكورافينيب مشكلات خطيرة في العين. تحدث إلى طبيبك على الفور إذا كنت تعاني من تغيم الرؤية، أو فقدان الرؤية، أو تغيرات أخرى في الرؤية (مثل وجود نقاط ملونة في مجال رؤيتك)، أو رؤية هالات (رؤية إطار ضبابي حول الأشياء)، أو ألم في العين أو احمرار العين أو تورمها. سيقوم طبيبك بفحص عينيك بحثًا عن أي مشكلات في رؤيتك أثناء تناولك ميكتوفي.</li></ul><p>&nbsp;</p><ul><li dir="RTL"><strong>مشكلات عضلية:</strong> يمكن أن يسبب ميكتوفي عند تناوله مع إنكورافينيب انحلال العضلات (انحلال الربيدات). سيقوم طبيبك بإجراء فحوصات دم للتحقق من مستوى إنزيم يسمى فسفوكيناز الكرياتين (CPK) الذي يمكن أن يكون علامة على إصابتك بمشكلات عضلية قبل وأثناء العلاج. كإجراء احتياطي: اشرب الكثير من السوائل أثناء العلاج. تحدث إلى طبيبك على الفور في حالة إصابتك بألم أو شد أو تيبس أو تقلص عضلي، أو بول بلون داكن مائل إلى الأحمر.</li></ul><p>&nbsp;</p><ul><li dir="RTL"><strong>ضغط الدم المرتفع:</strong> يمكن أن يسبب ميكتوفي عند تناوله مع إنكورافينيب ارتفاع ضغط الدم. سيتحقق طبيبك أو الممرضة من ضغط دمك قبل وأثناء العلاج بميكتوفي. تحدث إلى طبيبك على الفور إذا أُصبت بصداع شديد أو شعرت بالدوار أو الدوخة أو إذا كان ضغط دمك الذي يتم قياسه باستخدام جهاز ضغط الدم المنزلي أعلى بكثير من المعتاد.</li></ul><p>&nbsp;</p><ul><li dir="RTL"><strong>الجلطات الدموية:</strong> يمكن أن يسبب ميكتوفي عند تناوله مع إنكورافينيب جلطات دموية في ذراعيك أو ساقيك، وإذا انتقلت الجلطة إلى رئتيك فقد تؤدي إلى الوفاة. تحدث إلى طبيبك على الفور إذا شعرت بألم في الصدر، أو ضيق تنفس مفاجئ، أو صعوبة في التنفس، أو ألم في ساقيك مع أو دون تورم، أو تورم في ذراعيك وساقيك، أو أصبت بالبرودة والشحوب في إحدى الذراعين أو الساقين. إذا لزم الأمر، فقد يقوم طبيبك بإيقاف علاجك بشكل مؤقت أو بشكل نهائي.</li></ul><p>&nbsp;</p><ul><li dir="RTL"><strong>مشكلات في الرئة أو التنفس:</strong> قد يسبب ميكتوفي عند تناوله مع إنكورافينيب مشكلات في الرئة أو التنفس بما في ذلك التهاب الرئتين (الالتهاب الرئوي أو المرض الرئوي الخلالي)؛ يمكن أن تتضمن العلامات والأعراض: السعال، أو ضيق التنفس، أو الإرهاق. إذا لزم الأمر، فقد يقوم طبيبك بإيقاف علاجك بشكل مؤقت أو بشكل نهائي.</li></ul><p>&nbsp;</p><ul><li dir="RTL"><strong>تغيرات جلدية:</strong> قد يؤدي تناول ميكتوفي مع إنكورافينيب إلى الإصابة بأنواع أخرى من سرطان الجلد، مثل سرطانة الخلايا الحرشفية الجلدية أو سرطانة الخلايا القاعدية. سيقوم طبيبك بفحص جلدك قبل بدء العلاج، وكل شهرين أثناء العلاج، ولمدة تصل إلى ٦ أشهر بعد توقفك عن تناول هذين الدواءين بحثًا عن أي سرطانات جلدية جديدة. أخبر طبيبك على الفور إذا اكتشفت تغيرات جلدية أثناء وبعد العلاج بما في ذلك: الثآليل حديثة الظهور، أو القرح الجلدية، أو النتوءات المائلة للون الأحمر التي تنزف أو لا تُشفى، أو تغير في حجم أو لون شامة.</li></ul><p dir="RTL">بالإضافة إلى ذلك، يحتاج طبيبك إلى التحقق من إصابتك بسرطانة الخلايا الحرشفية في رأسك، وعنقك، وفمك، وغددك الليمفاوية، وستخضع لفحوصات بالتصوير المقطعي المحوسب (CT) بانتظام. وهذا إجراء احتياطي تحسبًا لظهور سرطانة الخلايا الحرشفية داخل جسمك. يوصى أيضًا بإجراء فحوصات للأعضاء التناسلية (في النساء) وفحوصات شرجية قبل بدء العلاج وفي نهايته.</p><p>&nbsp;</p><ul><li dir="RTL"><strong>مشكلات في الكبد:</strong> يمكن أن يتسبب ميكتوفي عند تناوله مع إنكورافينيب في نتائج غير طبيعية لفحوصات الدم فيما يتعلق بكبدك (ارتفاع مستويات إنزيمات الكبد). سيقوم طبيبك بإجراء فحوصات دم لفحص كبدك قبل وأثناء العلاج. تحدث إلى طبيبك إذا ظهرت لديك أي علامات وأعراض لمشكلة في الكبد مثل اصفرار الجلد والعينين والبول الداكن أو البني (بلون الشاي)، والغثيان أو القيء، والتعب والتكدم والنزيف وفقدان الشهية.</li></ul><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;الأطفال والمراهقون</strong></p><p dir="RTL">يوصى بعدم استخدام ميكتوفي لعلاج الأطفال والمراهقين الذين تقل أعمارهم عن ١٨ عامًا. لم تتم دراسة هذا الدواء في هذه الفئة العمرية.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرضة، إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;قد تؤثر بعض الأدوية على طريقة عمل ميكتوفي أو تزيد من احتمالية إصابتك بأعراض جانبية. أخبر طبيبك على وجه الخصوص إذا كنت تتناول أيًا من الأشياء المدرجة في هذه القائمة أو أي أدوية أخرى:</p><ul><li dir="RTL">بعض الأدوية التي تستخدم لعلاج العدوى البكتيرية مثل ريفامبيسين، سيبروفلوكساسين</li><li dir="RTL">بعض الأدوية التي تستخدم عادة لعلاج الصرع مثل فينوباربيتال، فينيتوين، كاربامازيبين</li><li dir="RTL">بعض الأدوية التي تستخدم لعلاج فيروس نقص المناعة البشرية (HIV) مثل إندينافير، أتازانافير</li><li dir="RTL">دواء يستخدم لعلاج سرطانة الخلايا يسمى سورافينيب</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج عشبي للاكتئاب: نبتة سانت جون</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء يستخدم لعلاج الاكتئاب مثل دولوكستين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء يستخدم عادة لعلاج ارتفاع مستوى الكولستيرول مثل برافاستاتين</p><ul><li dir="RTL">دواء يستخدم لعلاج مشكلات التنفس، ثيوفيلين.</li></ul><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">الحمل</p><p dir="RTL">لا يوصى بتناول ميكتوفي أثناء الحمل. فقد يسبب ضررًا أو عيوبًا ولادية للجنين بشكل دائم.</p><p dir="RTL">إذا كنتِ حاملًا أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ قبل تناول هذا الدواء.</p><p dir="RTL">إذا كنتِ امرأة قادرة على الإنجاب، يجب عليكِ استخدام وسيلة منع حمل موثوقة أثناء تناولكِ ميكتوفي ويجب عليكِ الاستمرار في استخدام وسيلة منع حمل موثوقة لمدة ٣٠ يومًا على الأقل بعد تناول آخر جرعة من الدواء. تواصلي مع طبيبكِ فورًا إذا أصبحتِ حاملًا خلال فترة تناول ميكتوفي.</p><p>&nbsp;</p><p dir="RTL">الرضاعة الطبيعية</p><p dir="RTL">لا يوصى بتناول ميكتوفي خلال فترة الرضاعة الطبيعية. ولا يُعرف ما إذا كان ميكتوفي يمر إلى لبن الأم أم لا. إذا كنتِ ترضعين رضاعة طبيعية أو تخططين لذلك، فاستشيري طبيبكِ قبل تناول هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>تأثير ميكتوفي على القيادة واستخدام الآلات</strong></p><p dir="RTL">من الممكن أن يؤثر ميكتوفي على قدرتك على القيادة أو استخدام الآلات. تجنب القيادة أو استخدام الآلات إذا كنت تعاني من أي مشكلات في رؤيتك أو أي أعراض جانبية أخرى يمكنها التأثير على قدرتك على القيادة أو استخدام الآلات (انظر القسم ٤) خلال فترة تناول ميكتوفي. تحدث إلى طبيبك إذا لم تكن متأكدًا مما إذا كان يمكنك القيادة.</p><p>&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات ميكتوفي</strong></p><p dir="RTL"><br /><strong>يحتوي ميكتوفي على اللاكتوز</strong></p><p dir="RTL">إذا أخبرك طبيبك بأنك لا تتحمل بعض أنواع السكريات، فتحدث إليه قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الكمية التي ينبغي تناولها</strong></p><p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك أو الصيدلي. راجع طبيبك أو الصيدلي إذا لم تكن متأكدًا مما ينبغي لك فعله.</p><p>&nbsp;</p><p dir="RTL">تبلغ الجرعة الموصى بها من ميكتوفي ٤٥ ملجم (٣ أقراص بتركيز ١٥ ملجم) مرتين يوميًا، تؤخذ بفارق زمني يبلغ ١٢ ساعة تقريبًا (أي ما يعادل جرعة يومية قدرها ٩٠ ملجم). ستتلقى أيضًا علاجًا بدواء آخر، وهو إنكورافينيب.</p><p>&nbsp;</p><p dir="RTL">إذا أصبت بأعراض جانبية خطيرة (مثل مشكلات القلب، أو العين، أو الجلد)، فقد يقلل طبيبك الجرعة أو يوقف العلاج مؤقتًا أو نهائيًا.</p><p>&nbsp;</p><p dir="RTL"><strong>طريقة استخدام ميكتوفي</strong></p><p dir="RTL">يمكن تناول ميكتوفي مع الطعام أو بين الوجبات.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا أصبت بالقيء</strong></p><p dir="RTL">إذا تقيأت في أي وقت بعد تناول ميكتوفي، فلا تتناول جرعة إضافية. تناول الجرعة التالية حسب ما هو مقرر.</p><p>&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من ميكتوفي</strong></p><p dir="RTL">إذا تناولت عددًا من الأقراص أكثر مما ينبغي، فتواصل مع طبيبك أو الصيدلي أو الممرضة فورًا. أرِهم هذه النشرة وعبوة الدواء إن أمكن.</p><p>&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة ميكتوفي</strong></p><p dir="RTL">إذا فاتتك إحدى جرعات ميكتوفي، فتناولها بمجرد تذكرها. ولكن إذا مر أكثر من ٦ ساعات على موعد الجرعة الفائتة، فتخط تلك الجرعة وتناول جرعتك التالية في الموعد المعتاد. ثم استمر في تناول أقراصك في مواعيد منتظمة كالمعتاد.</p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض جرعة منسية.</p><p>&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول ميكتوفي</strong></p><p dir="RTL">من المهم تناول ميكتوفي طوال الفترة التي يحددها طبيبك. لا تتوقف عن تناول هذا الدواء إلا إذا أخبرك طبيبك بذلك.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي أو الممرضة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، إلا أنها لا تصيب الجميع.</p><p>&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الخطيرة</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>قد يسبب ميكتوفي أعراضًا جانبية خطيرة. أخبر طبيبك فورًا</strong> إذا أصبت بأي من الأعراض الجانبية الخطيرة التالية، سواءً لأول مرة أو إذا تفاقمت (انظر أيضًا القسم ٢).</p><p>&nbsp;</p><p dir="RTL"><strong>مشكلات في القلب:</strong> يمكن أن يؤثر ميكتوفي على كفاءة عمل قلبك (انخفاض الكسر القذفي للبطين الأيسر)؛ وقد تتضمن العلامات والأعراض ما يلي:</p><ul><li dir="RTL">&nbsp;الشعور بالدوار أو التعب أو الدوخة</li></ul><ul><li dir="RTL">ضيق التنفس</li><li dir="RTL">الشعور بأن قلبك يخفق بشدة أو ضرباته متسارعة أو ينبض بشكل غير منتظم</li><li dir="RTL">تورم الساقين (الكاحلين والقدمين)</li></ul><p>&nbsp;</p><p dir="RTL"><strong>ضغط الدم المرتفع:</strong> يمكن أن يسبب ميكتوفي ارتفاع ضغط الدم. أخبر طبيبك على الفور إذا أصبت بصداع شديد أو شعرت بالدوار أو الدوخة أو إذا كان ضغط دمك الذي يتم قياسه باستخدام جهاز ضغط الدم المنزلي أعلى بكثير من المعتاد.</p><p>&nbsp;</p><p dir="RTL"><strong>الجلطات الدموية:</strong> يمكن أن يسبب ميكتوفي جلطات دموية (الانصمام الخثاري الوريدي، بما في ذلك الانصمام الرئوي)؛ قد تتضمن العلامات والأعراض ما يلي:</p><ul><li dir="RTL">ألم الصدر</li><li dir="RTL">ضيق التنفس المفاجئ أو صعوبة التنفس</li><li dir="RTL">ألم في ساقيك مع أو دون تورم</li><li dir="RTL">تورم في ذراعيك وساقيك</li><li dir="RTL">برودة وشحوب إحدى الذراعين أو الساقين</li></ul><p>&nbsp;</p><p dir="RTL"><strong>مشكلات في العين:</strong> يمكن أن يسبب ميكتوفي تسرب السائل تحت شبكية العين، مما يؤدي إلى انفصال الطبقات المختلفة في العين (انفصال الصباغ الظهاري الشبكي)، الذي قد يؤدي إلى ما يلي:</p><ul><li dir="RTL">تغيم الرؤية، أو فقدان الرؤية، أو حدوث تغيرات أخرى في الرؤية (مثل ظهور نقاط ملونة في مجال رؤيتك)</li><li dir="RTL">رؤية هالات (رؤية إطار ضبابي حول الأشياء)</li><li dir="RTL">ألم أو تورم أو احمرار العين</li></ul><p>&nbsp;</p><p dir="RTL"><strong>مشكلات عضلية:</strong> يمكن أن يسبب ميكتوفي انحلال العضلات (انحلال الربيدات) الذي قد يؤدي إلى تلف الكلى ويمكن أن يكون مميتًا؛ ويمكن أن تتضمن العلامات والأعراض ما يلي:</p><ul><li dir="RTL">الألم، أو الشد، أو التيبس، أو التقلص العضلي</li><li dir="RTL">لون البول الداكن المائل إلى الأحمر</li></ul><p>&nbsp;</p><p dir="RTL"><strong>مشكلات نزيف:</strong> يمكن أن يسبب ميكتوفي مشكلات نزيف خطيرة. أخبر طبيبك فورًا إذا كنت تعاني من أي نزيف غير معتاد أو ظهرت عليك علامات للنزيف، بما في ذلك:</p><ul><li dir="RTL">&nbsp;الصداع، أو الدوار، أو الضعف</li><li dir="RTL">السعال المصحوب بخروج دم أو الجلطات الدموية</li><li dir="RTL">القيء الذي يحتوي على دم أو الذي يشبه &quot;ثفل القهوة&quot;</li><li dir="RTL">براز أحمر أو أسود اللون يشبه القطران</li><li dir="RTL">خروج دم في البول</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ألم المعدة (البطن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف مهبلي غير معتاد</p><p>&nbsp;</p><p dir="RTL"><strong>سرطانات الجلد الأخرى:</strong> عند تناول ميكتوفي بالتزامن مع إنكورافينيب، قد يصاب المريض بأنواع مختلفة من سرطانات الجلد مثل سرطانة الخلايا الحرشفية الجلدية. وعادة ما تكون هذه السرطانات الجلدية (انظر أيضًا القسم ٢) محصورة في منطقة صغيرة، ويمكن إزالتها جراحيًا والاستمرار في العلاج بميكتوفي (وإنكورافينيب) دون توقف.</p><p>&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الأخرى عند تناول ميكتوفي وإنكورافينيب معًا:</strong></p><p dir="RTL">بالإضافة إلى الأعراض الجانبية الخطيرة المذكورة أعلاه، قد يصاب الأشخاص الذين يتناولون ميكتوفي وإنكورافينيب معًا أيضًا بالأعراض الجانبية التالية.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأعراض الجانبية الأكثر شيوعًا عند تناول ميكتوفي مع إنكورافينيب لعلاج الورم الميلانيني تتضمن:</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإرهاق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p></td><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في منطقة المعدة (البطن)</p></td></tr></tbody></table><p dir="RTL"><strong>تشمل الأعراض الجانبية الأكثر شيوعًا لميكتوفي عند تناوله مع</strong> <strong>إنكورافينيب</strong> <strong>لعلاج</strong> <strong>سرطان الرئة ذو الخلايا غير الصغيرة</strong> <strong>ما يلي</strong>:</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:606px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام العضلات أو المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في منطقة المعدة (البطن)</p></td><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية، أو فقدان الرؤية، أو تغيرات أخرى في الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سُعال</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي أعراض جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن هذا أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p>&nbsp;</p><ul><li dir="RTL"><strong>المملكة العربية السعودية</strong></li></ul><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><ul><li dir="RTL">مركز الاتصال الموحد: ١٩٩٩٩</li><li dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</li><li dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa</li></ul></td></tr></tbody></table><p><u>&nbsp;</u></p><ul><li dir="RTL">&nbsp;<strong>دول الخليج الأخرى</strong></li></ul><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ في درجة حرارة أقل من ٣٠ درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المُدون على شريط البليستر والعبوة الكرتونية، بعد الرمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير في حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;المادة الفعالة هي بينيميتينيب. يحتوي كل قرص مغلف بطبقة رقيقة على ١٥ ملجم من بينيميتينيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;المكونات الأخرى هي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلب القرص: لاكتوز أحادي الهيدرات، وسليولوز دقيق التبلور (E460i)، وسيليكا غروانية لا مائية (E551)، وكروسكارميلوز الصوديوم (E468)، وستيارات المغنيسيوم (E470b). انظر القسم ٢ &quot;يحتوي ميكتوفي على اللاكتوز&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطبقة الرقيقة المغلفة للأقراص: كحول البولي فينيل (E1203)، وماكروجول ٣٣٥٠ (E1521)، وثاني أكسيد التيتانيوم (E171)، والتالك (E533b)، وأكسيد الحديد الأصفر (E172)، وأكسيد الحديد الأسود (E172).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص ميكتوفي المغلفة بطبقة رقيقة هي أقراص بيضاوية غير محززة ومحدبة الوجهين باللون الأصفر إلى الأصفر الداكن ومغلفة بطبقة رقيقة، مطبوع على أحد جانبيها &quot;A&quot; بنمط خط مميز و&quot;15&quot; على الجانب الآخر.</p><p>&nbsp;</p><p dir="RTL">يتوفر ميكتوفي في عبوة تحتوي على ٨٤ قرصًا (٧ شرائط بليستر يحتوي كل منها على ١٢ قرصًا).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;مالك رخصة التسويق</strong></p><p dir="RTL">&rlm;فايزر يوروب إم أي إي إي جي</p><p dir="RTL">بروكسل، بلجيكا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة الصانعة</strong></p><p dir="RTL">ألماك فارما سيرفيسيس ليميتد</p><p dir="RTL">بورتداون، جريجافون، المملكة المتحدة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شركة التغليف والفسح النهائي</strong></p><p dir="RTL">بيرفابر ميديسامينت برودكشن</p><p dir="RTL">موقع بروجيفارم، جين، فرنسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             أكتوبر ٢٠٢٣
	

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MEKTOVI 15 mg film-coated tablets


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EBinimetinib is a kinase inhibitor. The chemical name is 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide. The molecular formula is C17H15BrF2N4O3 and the molecular weight is 441.2 daltons. The chemical structure of binimetinib is shown below:
 
Binimetinib is a white to slightly yellow powder. In aqueous media, binimetinib is slightly soluble at pH 1, very slightly soluble at pH 2, and practically insoluble at pH 4.5 and higher.
Each film coated tablet contains 15 mg of binimetinib.

Excipient with known effect
Each film coated tablet contains 133.5 mg of lactose monohydrate.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablet (tablet).

Yellow to dark yellow, unscored biconvex, oval film-coated tablets debossed with a stylized “A” on one side and “15” on the other side.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma</strong></p><p>MEKTOVI is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test (see sections&nbsp;4.2).</p><p>&nbsp;</p><p><strong>BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)</strong></p><p>MEKTOVI is indicated, in combination with encorafenib, for the treatment of adult patients with metastatic non small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. (see sections&nbsp;4.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patient Selection</p><p><u>BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma </u></p><p>Confirm the presence of a BRAF V600E or V600K mutation in tumor specimens prior to initiating MEKTOVI (see section 5.1)<em>. </em>Information on FDA-approved tests for the detection of BRAF V600E and V600K mutations in melanoma is available at: http://www.fda.gov/CompanionDiagnostics.</p><p><u>&nbsp;</u></p><p><u>BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)</u></p><p>Confirm the presence of a BRAF V600E mutation in tumor or plasma specimens prior to initiating MEKTOVI (see section 5.1)<em>. </em>If no mutation is detected in a plasma specimen, test tumor tissue. Information on FDA-approved tests for the detection of BRAF V600E mutations in NSCLC is available at: http://www.fda.gov/CompanionDiagnostics.</p><p>&nbsp;</p><p><u>Posology</u></p><p><u>&nbsp;</u></p><p>The recommended dosage of MEKTOVI is 45 mg orally taken twice daily, approximately 12 hours apart, in combination with encorafenib until disease progression or unacceptable toxicity. Refer to the encorafenib prescribing information for recommended encorafenib dosing information.</p><p>&nbsp;</p><p>MEKTOVI may be taken with or without food (see section 5.2). Do not take a missed dose of MEKTOVI within 6 hours of the next dose of MEKTOVI.</p><p>&nbsp;</p><p>Do not take an additional dose if vomiting occurs after MEKTOVI administration but continue with the next scheduled dose.</p><p>&nbsp;</p><p><em><u>Dose modification</u></em></p><p>The management of adverse reactions may require dose reduction, temporary interruption or treatment discontinuation (see below, Table&nbsp;1 and Table&nbsp;2).</p><p>&nbsp;</p><p>If encorafenib is permanently discontinued, discontinue MEKTOVI.</p><p>Dose reductions for adverse reactions associated with MEKTOVI are presented in Table&nbsp;1.</p><p>Table&nbsp;1: Recommended Dose Reductions for MEKTOVI for Adverse Reactions</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Action</p></td><td style="vertical-align:top"><p>Recommended Dose</p></td></tr><tr><td style="vertical-align:top"><p>First Dose Reduction</p></td><td style="vertical-align:top"><p>30 mg orally twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Subsequent Modification</p></td><td style="vertical-align:top"><p>Permanently discontinue if unable to tolerate MEKTOVI 30 mg orally twice daily</p></td></tr></tbody></table><p>Dosage modifications for adverse reactions associated with MEKTOVI are presented in Table&nbsp;2.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="2" style="vertical-align:top"><p>Table&nbsp;2: Recommended Dosage Modifications for MEKTOVI for Adverse Reactions</p></td></tr><tr><td style="vertical-align:top"><p>Severity of Adverse Reaction<sup>a</sup></p></td><td style="vertical-align:top"><p>Dose Modification for MEKTOVI</p></td></tr></thead><tbody><tr><td colspan="2" style="vertical-align:top"><p>Cardiomyopathy (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Asymptomatic, absolute decrease in LVEF of greater than 10% from baseline that is also below lower limit of normal (LLN)</p></td><td style="vertical-align:top"><p>Withhold MEKTOVI for up to 4 weeks, evaluate LVEF every 2&nbsp;weeks.</p><p>Resume MEKTOVI at a reduced dose if the following are present:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LVEF is at or above the lower limit of normal <u>and</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Absolute decrease from baseline is 10% or less <u>and</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient is asymptomatic.</p><p>If the LVEF does not recover within 4 weeks permanently discontinue MEKTOVI.</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Symptomatic congestive heart failure or absolute decrease in LVEF of greater than 20% from baseline that is also below LLN</p></td><td style="vertical-align:top"><p>Permanently discontinue MEKTOVI.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Venous Thromboembolism (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncomplicated deep venous thrombosis (DVT) or pulmonary embolism (PE)</p></td><td style="vertical-align:top"><p>Withhold MEKTOVI.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If improves to Grade 0-1, resume at a reduced dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If no improvement, permanently discontinue MEKTOVI.</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Life threatening PE</p></td><td style="vertical-align:top"><p>Permanently discontinue MEKTOVI.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Serous Retinopathy</em> (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Symptomatic serous retinopathy/Retinal pigment epithelial detachments</p></td><td style="vertical-align:top"><p>Withhold MEKTOVI for up to 10 days.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If improves and becomes asymptomatic, resume at same dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If not improved, resume at a lower dose level or permanently discontinue MEKTOVI.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Retinal Vein Occlusion (RVO) (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any Grade</p></td><td style="vertical-align:top"><p>Permanently discontinue MEKTOVI.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Uveitis (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 1-3</p></td><td style="vertical-align:top"><p>If Grade 1 or 2 does not respond to specific ocular therapy, or for Grade 3 uveitis, withhold MEKTOVI for up to 6 weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If improved, resume at same or reduced dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If not improved, permanently discontinue MEKTOVI.</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 4</p></td><td style="vertical-align:top"><p>Permanently discontinue MEKTOVI.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Interstitial Lung Disease </em>(see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 2</p></td><td style="vertical-align:top"><p>Withhold MEKTOVI for up to 4 weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If improved to Grade 0-1, resume at a reduced dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If not resolved within 4 weeks, permanently discontinue MEKTOVI.</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 3 or Grade 4</p></td><td style="vertical-align:top"><p>Permanently discontinue MEKTOVI.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Hepatotoxicity </em>(see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 2<strong> </strong>AST or ALT increased</p></td><td style="vertical-align:top"><p>Maintain MEKTOVI dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If no improvement within 2 weeks, withhold MEKTOVI until improved to Grade 0-1 or to pretreatment/baseline levels and then resume at the same dose.&nbsp; <strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 3 or 4 AST or ALT increased</p></td><td style="vertical-align:top"><p>See <em>Other Adverse Reactions.</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Rhabdomyolysis or Creatine Phosphokinase (CPK) elevations (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 4 asymptomatic CPK elevation or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any Grade CPK elevation with symptoms or with renal impairment</p></td><td style="vertical-align:top"><p>Withhold MEKTOVI dose for up to 4 weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If improved to Grade 0-1 resume at a reduced dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If not resolved within 4 weeks, permanently discontinue MEKTOVI.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Dermatologic [other than palmar plantar erythrodysesthesia syndrome (PPES)] (see section 4.8)</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 2</p></td><td style="vertical-align:top"><p>If no improvement within 2 weeks, withhold MEKTOVI until Grade 0-1. Resume at same dose if first occurrence or reduce dose if recurrent.</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 3</p></td><td style="vertical-align:top"><p>Withhold MEKTOVI until Grade 0-1. Resume at same dose if first occurrence or reduce dose if recurrent.</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 4</p></td><td style="vertical-align:top"><p>Permanently discontinue MEKTOVI.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Other Adverse Reactions (including Hemorrhage) (see section 4.4, section 4.8<sup>b</sup>)</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recurrent Grade 2 or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First occurrence of any Grade 3</p></td><td style="vertical-align:top"><p>Withhold MEKTOVI for up to 4 weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If improves to Grade 0-1 or to pretreatment/baseline levels, resume at reduced dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If no improvement, permanently discontinue MEKTOVI.</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First occurrence of any Grade 4</p></td><td style="vertical-align:top"><p>Permanently discontinue MEKTOVI, or</p><p>Withhold MEKTOVI for up to 4 weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If improves to Grade 0-1 or to pretreatment/baseline levels, then resume at a reduced dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If no improvement, permanently discontinue MEKTOVI.</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recurrent Grade 3</p></td><td style="vertical-align:top"><p>Consider permanently discontinuing MEKTOVI.</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recurrent Grade 4</p></td><td style="vertical-align:top"><p>Permanently discontinue MEKTOVI.</p></td></tr></tbody></table><p>a. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.</p><p>b. Dose modification of MEKTOVI when administered with encorafenib is not recommended for the following adverse reactions: palmar‑plantar erythrodysesthesia syndrome (PPES), non-cutaneous RAS mutation-positive malignancies, and QTc prolongation.</p><p>Refer to the encorafenib prescribing information for dose modifications for adverse reactions associated with encorafenib.</p><p>&nbsp;</p><p><em>Duration of treatment</em></p><p>Treatment should continue until the patient no longer derives benefit or the development of unacceptable toxicity.</p><p><em>&nbsp;</em></p><p><em>Missed doses</em></p><p>Do not take a missed dose of MEKTOVI within 6 hours of the next dose of MEKTOVI.</p><p><em>&nbsp;</em></p><p><em>Vomiting</em></p><p>Do not take an additional dose if vomiting occurs after MEKTOVI administration but continue with the next scheduled dose.</p><p><em>&nbsp;</em></p><p><em><u>Special populations</u></em></p><p><em><u>&nbsp;</u></em></p><p><em>Elderly patients</em></p><p>Of the 690 patients with BRAF mutation-positive melanoma who received MEKTOVI in combination with encorafenib across multiple clinical trials, 20% were aged 65 to 74 years and 8% were aged 75 years and older (see section&nbsp;5.2).</p><p>&nbsp;</p><p>Of the 98 patients with BRAF V600E mutation-positive metastatic NSCLC who received MEKTOVI in combination with encorafenib, 62 (63.2%) were 65 years of age and over and 20 (20.4%) were 75 years and over (see section 5.1).</p><p>&nbsp;</p><p>No overall differences in the safety or effectiveness of MEKTOVI plus encorafenib were observed in older patients as compared to younger patients.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Binimetinib concentrations may increase in patients with moderate or severe hepatic impairment. Dose adjustment for MEKTOVI is not recommended in patients with mild hepatic impairment (total bilirubin &gt; 1 and &le; 1.5 &times; ULN and any AST or total bilirubin &le; ULN and AST &gt; ULN). Reduce the dose of MEKTOVI for patients with moderate (total bilirubin &gt; 1.5 and &le; 3 &times; ULN and any AST) or severe (total bilirubin levels &gt; 3 &times; ULN and any AST) hepatic impairment.</p><p>&nbsp;</p><p>For patients with moderate (total bilirubin greater than 1.5 and less than or equal to 3 &times; ULN and any AST) or severe (total bilirubin levels greater than 3 &times; ULN and any AST) hepatic impairment, the recommended dosage is 30 mg orally taken twice daily (see section 5.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment is recommended for patients with renal impairment (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and effectiveness of MEKTOVI have not been established in pediatric patients.</p><p><u>&nbsp;</u></p><p><u>Method of administration </u></p><p><u>&nbsp;</u></p><p>MEKTOVI is for oral use.</p><p>The tablets may be taken with or without food (see section&nbsp;5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Binimetinib is to be given in combination with encorafenib. For additional information on warnings and precautions associated with encorafenib treatment, see section&nbsp;4.4 of encorafenib SmPC.</p><p><strong>&nbsp;</strong></p><p>New Primary Malignancies</p><p>New primary malignancies, cutaneous and non-cutaneous, can occur when MEKTOVI is used in combination with encorafenib.</p><p>&nbsp;</p><p>In PHAROS, cutaneous squamous cell carcinoma and skin papilloma each occurred in 2% of patients who received MEKTOVI in combination with encorafenib.</p><p>&nbsp;</p><p>Monitor patients for new malignancies prior to initiation of treatment, while on treatment, and after discontinuation of treatment (see section 4.2)<em>.</em></p><p>&nbsp;</p><p>Cardiomyopathy</p><p>Cardiomyopathy, manifesting as left ventricular dysfunction associated with symptomatic or asymptomatic decreases in ejection fraction, has been reported in patients treated with MEKTOVI in combination with encorafenib. In COLUMBUS, evidence of cardiomyopathy (decrease in LVEF below the institutional LLN with an absolute decrease in LVEF &ge;10% below baseline as detected by echocardiography or MUGA) occurred in 7% of patients receiving MEKTOVI plus encorafenib. Grade 3 left ventricular dysfunction occurred in 1.6% of patients. The median time to first occurrence of left ventricular dysfunction (any grade) in patients receiving MEKTOVI in combination with encorafenib was 3.6 months (range 0 to 21 months). Cardiomyopathy resolved in 87% of patients receiving MEKTOVI plus encorafenib.</p><p>&nbsp;</p><p>In PHAROS, evidence of cardiomyopathy (decrease in LVEF below the institutional LLN with an absolute decrease in LVEF &ge;10% below baseline as detected by echocardiography or MUGA) occurred in 11% of patients receiving MEKTOVI in combination with encorafenib. Grade 3 left ventricular dysfunction occurred in 1% of patients. Cardiomyopathy resolved in 82% of patients receiving MEKTOVI plus encorafenib.</p><p>&nbsp;</p><p>Assess ejection fraction by echocardiogram or MUGA scan prior to initiating treatment, one month after initiating treatment, and then every 2 to 3 months during treatment. The safety of MEKTOVI in combination with encorafenib has not been established in patients with a baseline ejection fraction that is either below 50% or below the institutional lower limit of normal (LLN). Patients with cardiovascular risk factors should be monitored closely when treated with MEKTOVI.</p><p>Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction (see section 4.2 and 4.8)<em>.</em></p><p>&nbsp;</p><p>Venous Thromboembolism</p><p>In COLUMBUS, venous thromboembolism (VTE) occurred in 6% of patients receiving MEKTOVI in combination with encorafenib, including 3.1% of patients who developed pulmonary embolism. In PHAROS, VTE occurred in 7% of patients receiving MEKTOVI in combination with encorafenib, including 1% of patients who developed pulmonary embolism.</p><p>&nbsp;</p><p>Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction (see section 4.2 and 4.8)<em>.</em></p><p>&nbsp;</p><p><strong>Ocular Toxicities</strong></p><p>Serous Retinopathy</p><p>In COLUMBUS, serous retinopathy occurred in 20% of patients treated with MEKTOVI in combination with encorafenib; 8% were retinal detachment and 6% were macular edema. Symptomatic serous retinopathy occurred in 8% of patients with no cases of blindness. No patient discontinued MEKTOVI due to serous retinopathy; 6% of patients required dose interruptions or dose reductions. The median time to onset of the first event of serous retinopathy (all grades) was 1.2 months (range 0&nbsp;to 17.5 months).</p><p>&nbsp;</p><p>In PHAROS, serous retinopathy (retinal detachment) occurred in 2% of patients with no cases of blindness treated with MEKTOVI in combination with encorafenib. No patient permanently discontinued MEKTOVI due to serous retinopathy; 1% of patients required dose interruptions.</p><p>&nbsp;</p><p>Assess for visual symptoms at each visit. Perform an ophthalmologic examination at regular intervals, for new or worsening visual disturbances, and to follow new or persistent ophthalmologic findings. Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction (see section 4.2 and 4.8)<em>.</em></p><p>&nbsp;</p><p>Retinal Vein Occlusion</p><p>RVO is a known class-related adverse reaction of MEK inhibitors and may occur in patients treated with MEKTOVI in combination with encorafenib. In patients with BRAF mutation-positive melanoma receiving MEKTOVI with encorafenib (n=690), 1 patient experienced RVO (0.1%).</p><p>&nbsp;</p><p>The safety of MEKTOVI has not been established in patients with a history of RVO or current risk factors for RVO including uncontrolled glaucoma or a history of hyperviscosity or hypercoagulability syndromes.&nbsp;</p><p>&nbsp;</p><p>Perform ophthalmologic evaluation for patient-reported acute vision loss or other visual disturbance within 24 hours. Permanently discontinue MEKTOVI in patients with documented RVO (see section 4.2 and 4.8)<em>.</em></p><p>&nbsp;</p><p>Uveitis</p><p>Uveitis, including iritis and iridocyclitis, has been reported in patients treated with MEKTOVI in combination with encorafenib. In COLUMBUS, the incidence of uveitis among patients treated with MEKTOVI in combination with encorafenib was 4%. In PHAROS, uveitis occurred in 1% of patients receiving MEKTOVI in combination with encorafenib.</p><p>Assess for visual symptoms at each visit. Perform an ophthalmologic evaluation at regular intervals and for new or worsening visual disturbances, and to follow new or persistent ophthalmologic findings. Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction (see section 4.2 and 4.8)<em>.</em></p><p><u>&nbsp;</u></p><p>Interstitial Lung Disease</p><p>In patients with BRAF mutation-positive melanoma receiving MEKTOVI with encorafenib (n=690), 2&nbsp;patients (0.3%) developed interstitial lung disease (ILD), including pneumonitis. In PHAROS, 1&nbsp;patient&nbsp;(1%) receiving MEKTOVI with encorafenib developed pneumonitis.</p><p>&nbsp;</p><p>Assess new or progressive unexplained pulmonary symptoms or findings for possible ILD. Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction (see section 4.2 and 4.8)<em>.</em></p><p>&nbsp;</p><p>Hepatotoxicity</p><p>Hepatotoxicity can occur when MEKTOVI is administered in combination with encorafenib. In COLUMBUS, the incidence of Grade 3 or 4 increases in liver function laboratory tests in patients receiving MEKTOVI in combination with encorafenib was 6% for alanine aminotransferase (ALT), 2.6% for aspartate aminotransferase (AST), and 0.5% for alkaline phosphatase. No patient experienced Grade 3 or 4 serum bilirubin elevation. In PHAROS, the incidence of Grade 3 or 4 increases in liver function laboratory tests in patients receiving MEKTOVI in combination with encorafenib was 10% for AST, 9% for ALT, and 3.2% for alkaline phosphatase.</p><p>&nbsp;</p><p>Monitor liver laboratory tests before initiation of MEKTOVI, monthly during treatment, and as clinically indicated. Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction (see section 4.2 and 4.8)<em>.</em></p><p><em>&nbsp;</em></p><p>Rhabdomyolysis</p><p>Rhabdomyolysis can occur when MEKTOVI is administered in combination with encorafenib. In COLUMBUS, elevation of laboratory values of serum CPK occurred in 58% of patients treated with MEKTOVI in combination with encorafenib. In patients with BRAF mutation-positive melanoma receiving MEKTOVI with encorafenib (n=690), rhabdomyolysis was reported in 1 patient (0.1%). In PHAROS, elevation of laboratory values of serum creatine kinase (CK) occurred in 41% of patients treated with MEKTOVI in combination with encorafenib. No patient experienced rhabdomyolysis.</p><p>&nbsp;</p><p>Monitor CPK and creatinine levels prior to initiating MEKTOVI, periodically during treatment, and as clinically indicated. Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction<em> (see section 4.2 and 4.8).</em></p><p>&nbsp;</p><p>Hemorrhage</p><p>Hemorrhage can occur when MEKTOVI is administered in combination with encorafenib. In COLUMBUS, hemorrhage occurred in 19% of patients receiving MEKTOVI in combination with encorafenib. Grade 3 or greater hemorrhage occurred in 3.2% of patients. The most frequent hemorrhagic events were gastrointestinal, including rectal hemorrhage (4.2%), hematochezia (3.1%), and hemorrhoidal hemorrhage&nbsp;(1%). Fatal intracranial hemorrhage in the setting of new or progressive brain metastases occurred in 1.6% of patients.</p><p>&nbsp;</p><p>In PHAROS, hemorrhage occurred in 12% of patients receiving MEKTOVI in combination with encorafenib including fatal hemorrhage intracranial (1%); Grade 3 or 4 hemorrhage occurred in 4.1% of patients. The most frequent hemorrhagic events were anal hemorrhage and hemothorax (2% each).</p><p>Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction (see section 4.2 and 4.8)<em>.</em></p><p>&nbsp;</p><p>Embryo-Fetal Toxicity</p><p>Based on findings from animal studies and its mechanism of action, MEKTOVI can cause fetal harm when administered to a pregnant woman. Binimetinib was embryotoxic and abortifacient when administered to rabbits during the period of organogenesis at doses greater than or equal to those resulting in exposures approximately 5 times the human exposure at the recommended clinical dose of 45 mg twice daily.</p><p>&nbsp;</p><p>Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with MEKTOVI and for 30 days after the last dose (see section 4.6)<em>.</em></p><p>&nbsp;</p><p>Risks Associated with Combination Treatment</p><p>MEKTOVI is indicated for use in combination with encorafenib. Refer to the encorafenib prescribing information for additional risk information that applies to combination use treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical Studies</p><p><em>Effect of UGT1A1 Inducers or Inhibitors on Binimetinib</em>: UGT1A1 genotype and smoking (UGT1A1 inducer) do not have a clinically important effect on binimetinib exposure. Simulations predict similar C<sub>max</sub> of binimetinib 45 mg in the presence or absence of atazanavir 400 mg (UGT1A1 inhibitor).</p><p>No differences in binimetinib exposure have been observed when MEKTOVI is coadministered with encorafenib.</p><p><em>Effect of Binimetinib on CYP Substrates</em>: Binimetinib did not alter the exposure of a sensitive CYP3A4 substrate (midazolam).</p><p><em>Effect of </em><em>Acid Reducing Agents on Binimetinib</em>: The extent of binimetinib exposure (AUC) was not altered in the presence of a gastric acid reducing agent (rabeprazole).</p><p>In Vitro Studies</p><p><em>Effect of Binimetinib on CYP Substrates:</em> Binimetinib is not a time-dependent inhibitor of CYP1A2, CYP2C9, CYP2D6 or CYP3A.</p><p><em>Effect of Transporters on Binimetinib: </em>Binimetinib is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Binimetinib is not a substrate of organic anion transporting polypeptide (OATP1B1, OATP1B3, OATP2B1) or organic cation transporter 1 (OCT1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/Contraception in females</u></p><p>Based on animal data, MEKTOVI can cause fetal harm when administered to a pregnant woman.</p><p>&nbsp;</p><p><em>Pregnancy Testing</em></p><p>Verify the pregnancy status of females of reproductive potential prior to initiating MEKTOVI.</p><p><em>&nbsp;</em></p><p><em>Contraception</em></p><p>Females</p><p>Advise females of reproductive potential to use effective contraception during treatment with MEKTOVI and for 30 days after the last dose.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p><em>Risk Summary</em></p><p>Based on findings from animal reproduction studies and its mechanism of action (see section 5.1), MEKTOVI can cause fetal harm when administered to a pregnant woman. There are no available clinical data on the use of MEKTOVI during pregnancy. In animal reproduction studies, oral administration of binimetinib during the period of organogenesis was embryotoxic and an abortifacient in rabbits at doses greater than or equal to those resulting in exposures approximately 5 times the human exposure at the clinical dose of 45 mg twice daily <em>(see Data)</em>. Advise pregnant women and females of reproductive potential of the potential risk to a fetus.</p><p>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</p><p>&nbsp;</p><p><em>Data</em></p><p>Animal Data</p><p>In reproductive toxicity studies, administration of binimetinib to rats during the period of organogenesis resulted in maternal toxicity, decreased fetal weights and increased variations in ossification at doses &ge;30&nbsp;mg/kg/day (approximately 37 times the human exposure based on AUC at the recommended clinical dose of 45 mg twice daily). In pregnant rabbits, administration of binimetinib during the period of organogenesis resulted in maternal toxicity, decreased fetal body weights, an increase in malformations, and increased post-implantation loss, including total loss of pregnancy at doses &ge;10 mg/kg/day (approximately 5&nbsp;times the human exposure based on AUC at the recommended clinical dose of 45 mg twice daily). There was a significant increase in fetal ventricular septal defects and pulmonary trunk alterations at 20 mg/kg/day of binimetinib (less than 8 times the human exposure at the recommended clinical dose of 45 mg twice daily).</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p><em><u>Risk Summary</u></em></p><p>There are no data on the presence of binimetinib or its active metabolite in human milk, or the effects of binimetinib on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with MEKTOVI and for 3 days after the last dose.</p><p><u>&nbsp;</u></p><p><u>Fertility</u></p><p>&nbsp;</p><p>No dedicated fertility studies have been conducted with binimetinib in animals. In general toxicology studies in rats and monkeys, there were no remarkable findings in male or female reproductive organs.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Binimetinib has minor influence on the ability to drive or use machines. Visual disturbances have been reported in patients treated with binimetinib during clinical studies. Patients should be advised not to drive or use machines if they experience visual disturbances or any other adverse reaction that may affect their ability to drive and use machines (see sections&nbsp;4.4&nbsp;and&nbsp;4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following adverse reactions are described elsewhere in the labeling:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; New Primary Malignancies (see section 4.4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiomyopathy (see section 4.4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Venous Thromboembolism (see section 4.4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ocular Toxicities (see section 4.4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interstitial Lung Disease (see section 4.4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatotoxicity (see section 4.4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rhabdomyolysis (see section 4.4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hemorrhage (see section 4.4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Embryo-Fetal Toxicity (see section 4.4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Risks Associated with Combination Treatment (see section 4.4)</p><p>&nbsp;</p><p><strong>Clinical Trials Experience</strong></p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>&nbsp;</p><p>The data described in WARNINGS AND PRECAUTIONS reflect exposure of 192 patients with BRAF V600 mutation-positive unresectable or metastatic melanoma to MEKTOVI 45 mg twice daily in combination with encorafenib 450 mg once daily in a randomized open-label, active‑controlled trial (COLUMBUS) (see section 5.1) or, for rare events, exposure of 690 patients with BRAF V600 mutation‑positive melanoma to MEKTOVI 45&nbsp;mg twice daily in combination with encorafenib once daily across multiple clinical trials (NCT03915951, NCT01909453).</p><p>The pooled safety population described in the WARNINGS AND PRECAUTIONS also reflect exposure of 98 patients with BRAF V600E mutation-positive metastatic non-small cell lung cancer to MEKTOVI 45 mg twice daily and encorafenib 450 mg once daily until disease progression or unacceptable toxicity in PHAROS (see section 5.1).</p><p>&nbsp;</p><p><strong>BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma</strong></p><p>The data described below reflect exposure of 192 patients with BRAF V600 mutation-positive unresectable or metastatic melanoma to MEKTOVI (45 mg twice daily) in combination with encorafenib (450 mg once daily) in COLUMBUS.</p><p>&nbsp;</p><p>The COLUMBUS trial (see section 5.1) excluded patients with a history of Gilbert&rsquo;s syndrome, abnormal left ventricular ejection fraction, prolonged QTc (&gt;480 msec), uncontrolled hypertension, and history or current evidence of retinal vein occlusion. The median duration of exposure was 11.8 months for patients treated with MEKTOVI in combination with encorafenib and 6.2 months for patients treated with vemurafenib.</p><p>&nbsp;</p><p>The most common (&ge;25%) adverse reactions in patients receiving MEKTOVI in combination with encorafenib were fatigue, nausea, diarrhea, vomiting, and abdominal pain.</p><p>&nbsp;</p><p>Adverse reactions leading to dose interruptions of MEKTOVI occurred in 33% of patients receiving MEKTOVI in combination with encorafenib; the most common were left ventricular dysfunction (6%) and serous retinopathy (5%). Adverse reactions leading to dose reductions of MEKTOVI occurred in 19% of patients receiving MEKTOVI in combination with encorafenib; the most common were left ventricular dysfunction (3%), serous retinopathy (3%), and colitis (2%). Five percent (5%) of patients receiving MEKTOVI in combination with encorafenib experienced an adverse reaction that resulted in permanent discontinuation of MEKTOVI. The most common adverse reactions resulting in permanent discontinuation of MEKTOVI were hemorrhage in 2% and headache in 1% of patients.</p><p>&nbsp;</p><p>Table&nbsp;3 and Table&nbsp;4 present adverse drug reactions and laboratory abnormalities, respectively, identified in COLUMBUS. The COLUMBUS trial was not designed to demonstrate a statistically significant difference in adverse reaction rates for MEKTOVI in combination with encorafenib, as compared to vemurafenib, for any specific adverse reaction listed in Table&nbsp;3.</p><p>&nbsp;</p><p><strong>Table 3: Adverse Reactions Occurring in &ge; 10% of Patients Receiving MEKTOVI in Combination with Encorafenib in COLUMBUS<sup>a</sup></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td rowspan="2"><p>Adverse Reaction</p></td><td colspan="2"><p>MEKTOVI</p><p>with encorafenib</p><p>N=192</p></td><td colspan="2"><p>Vemurafenib</p><p>N=186</p></td></tr><tr><td><p>All</p><p>Grades</p><p>(%)</p></td><td><p>Grades</p><p>3 and 4<sup>b</sup></p><p>(%)</p></td><td><p>All</p><p>Grades</p><p>(%)</p></td><td><p>Grades</p><p>3 and 4<sup>b</sup></p><p>(%)</p></td></tr></thead><tbody><tr><td colspan="5" style="vertical-align:top"><p>General Disorders and Administration Site Conditions</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Fatigue<sup>c</sup></p></td><td style="vertical-align:top"><p>43</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Pyrexia<sup>c</sup></p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Peripheral edema<sup>c</sup></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Gastrointestinal Disorders</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Nausea</p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Diarrhea</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Vomiting<sup>c</sup></p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Abdominal pain<sup>c</sup></p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Constipation</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Skin and Subcutaneous Tissue Disorders</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Rash<sup>c</sup></p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>53</p></td><td style="vertical-align:top"><p>13</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Nervous System Disorders</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Dizziness<sup>c</sup></p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Visual Disorders</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Visual impairment<sup>c</sup></p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Serous retinopathy/RPED<sup>c</sup></p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Vascular Disorders</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Hemorrhage<sup>c</sup></p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Hypertension<sup>c</sup></p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>3</p></td></tr></tbody></table><p>a. Grades per National Cancer Institute CTCAE v4.03.</p><p>b.<strong> </strong>Grade 4 adverse reactions limited to diarrhea (n=1) and hemorrhage (n=3) in the MEKTOVI with encorafenib arm and constipation (n=1) in the vemurafenib arm.</p><p>c. Represents a composite of multiple, related preferred terms.</p><p>&nbsp;</p><p>Other clinically important adverse reactions occurring in &lt;10% of patients who received MEKTOVI in combination with encorafenib were:</p><p>Gastrointestinal disorders: <em>Colitis</em></p><p>Skin and subcutaneous tissue disorders: <em>Panniculitis</em><em>, Photosensitivity</em></p><p>Immune system disorders: <em>Drug </em><em>hypersensitivity</em></p><p>&nbsp;</p><p>Table&nbsp;4: Laboratory Abnormalities Occurring in &ge;10% (All grades) of Patients Receiving MEKTOVI in Combination with Encorafenib in COLUMBUS<sup>a</sup></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2"><p>Laboratory Abnormality</p></td><td colspan="2"><p>MEKTOVI</p><p>with encorafenib</p><p>N=192</p></td><td colspan="2"><p>Vemurafenib</p><p>N=186</p></td></tr><tr><td><p>All</p><p>Grades</p><p>(%)</p></td><td><p>Grades</p><p>3 and 4</p><p>(%)</p></td><td><p>All</p><p>Grades</p><p>(%)</p></td><td><p>Grades</p><p>3 and 4</p><p>(%)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Hematology</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Anemia</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>3.6</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>2.2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Leukopenia</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Lymphopenia</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>2.1</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Neutropenia</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>3.1</p></td><td style="vertical-align:top"><p>4.8</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Chemistry</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Increased Creatinine</p></td><td style="vertical-align:top"><p>93</p></td><td style="vertical-align:top"><p>3.6</p></td><td style="vertical-align:top"><p>92</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Increased Creatine Phosphokinase</p></td><td style="vertical-align:top"><p>58</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>3.8</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Increased Gamma Glutamyl Transferase</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>4.8</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Increased ALT</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>2.2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Increased AST</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>2.6</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>1.6</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Increased Alkaline Phosphatase</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>2.2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Hyponatremia</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>3.6</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>0.5</p></td></tr></tbody></table><p>a.&nbsp;&nbsp; Grades per National Cancer Institute CTCAE v4.03.</p><p>&nbsp;</p><p><strong>BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)</strong></p><p>The safety of MEKTOVI in combination with encorafenib is described in 98 patients with BRAF V600E mutation-positive metastatic NSCLC who received MEKTOVI (45 mg twice daily) in combination with encorafenib (450 mg once daily) in an open-label, single-arm trial (PHAROS).</p><p>&nbsp;</p><p>The PHAROS trial (see section 5.1) excluded patients with abnormal LVEF, prolonged QTc (&gt;480 ms), uncontrolled hypertension, and history or current evidence of retinal vein occlusion. The median duration of treatment for MEKTOVI and encorafenib was 8.4 and 9.2&nbsp;months respectively.</p><p>&nbsp;</p><p>The most common (&ge;25%) adverse reactions in patients receiving MEKTOVI were fatigue, nausea, diarrhea, musculoskeletal pain, vomiting, abdominal pain, visual impairment, constipation, dyspnea, rash, and cough.</p><p>&nbsp;</p><p>Adverse reactions leading to dose interruptions of MEKTOVI occurred in 62% of patients receiving MEKTOVI; the most common (&ge;5%) were diarrhea (17%); nausea (15%); fatigue (9%); AST increased&nbsp;(7%); ALT increased, anemia, musculoskeletal pain, vomiting (6% each); and acute kidney injury, hemorrhage, and LV dysfunction/cardiomyopathy (5% each). Adverse reactions leading to dose reductions of MEKTOVI occurred in 33% of patients receiving MEKTOVI; the most common (&ge;5%) were diarrhea&nbsp;(8%), nausea (6%), and AST increased (5%). A total of 17% of patients receiving MEKTOVI experienced an adverse reaction that resulted in permanent discontinuation of MEKTOVI; the most common (&ge;2%) were diarrhea&nbsp;(3.1%); musculoskeletal pain, LV dysfunction/cardiomyopathy, fatigue, nausea, rash, visual impairment, and vomiting (2% each). None of the other adverse reactions leading to permanent discontinuation of MEKTOVI occurred in more than 1 patient.</p><p>&nbsp;</p><p>Serious adverse reactions occurred in 38% of patients who received MEKTOVI in combination with encorafenib. Serious adverse reactions in &ge;2% of patients included hemorrhage (6%); diarrhea (4.1%); anemia, dyspnea, pneumonia (3.1% each); arrhythmia, device related infection, edema, myocardial infarction, and pleural effusion (2% each). Fatal adverse reactions occurred in 2% of patients who received MEKTOVI (45 mg twice‑daily) in combination with encorafenib, including intracranial hemorrhage and myocardial infarction (1% each).</p><p>&nbsp;</p><p>Table 5 and Table 6 present adverse drug reactions and laboratory abnormalities, respectively, identified in PHAROS.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Table 5: Adverse Reactions Occurring in &ge;10% of Patients Receiving MEKTOVI in Combination with Encorafenib in PHAROS<sup>a</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Adverse Reaction</p></td><td colspan="2" style="vertical-align:top"><p>MEKTOVI</p><p>with encorafenib<br />N=98</p></td></tr><tr><td style="vertical-align:top"><p>All</p><p>Grades</p><p>(%)</p></td><td style="vertical-align:top"><p>Grade 3 and 4<sup>b</sup></p><p>(%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>General</strong><strong> Disorders and Administration Site Conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fatigue<sup>c</sup></p></td><td style="vertical-align:top"><p>61</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>Edema<sup>d</sup></p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Gastrointestinal Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>58</p></td><td style="vertical-align:top"><p>3.1</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea<sup>e</sup></p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>37</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain<sup>f</sup></p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Eye Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Visual impairment<sup>g</sup></p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Musculoskeletal and Connective Tissue Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal pain<sup>h</sup></p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>4.1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rash<sup>i</sup></p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>3.1</p></td></tr><tr><td style="vertical-align:top"><p>Pruritis<sup>j</sup></p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Dry skin</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Respiratory, Thoracic and Mediastinal Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dyspnea<sup>k</sup></p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>Cough<sup>l</sup></p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous System Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness<sup>m</sup></p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Metabolism and Nutrition Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hemorrhage<sup>b,n</sup></p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>4.1</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Cardiac Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Left ventricular dysfunction/cardiomyopathy<sup>o</sup></p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Weight increased</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Psychiatric Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><p>a.&nbsp;&nbsp; Grades per National Cancer Institute CTCAE v4.03.</p><p>b.&nbsp;&nbsp; One Grade 5 adverse reaction of hemorrhage occurred.</p><p>c. Fatigue includes fatigue, asthenia.</p><p>d. Edema includes edema peripheral, generalized edema, swelling, localized edema, face edema.</p><p>e. Diarrhea includes diarrhea, colitis.</p><p>f. Abdominal pain includes abdominal pain, abdominal pain upper, abdominal discomfort, epigastric discomfort.</p><p>g. Visual impairment includes vision blurred, visual impairment, vitreous floaters, photophobia, visual acuity reduced, photopsia.</p><p>h. Musculoskeletal pain includes back pain, arthralgia, pain in extremity, myalgia, musculoskeletal chest pain, non-cardiac chest pain, neck pain.</p><p>i. Rash includes rash, rash macular, rash maculo-papular, rash papular, rash pustular, dermatitis acneiform, palmar-plantar erythrodysesthesia syndrome, eczema, skin exfoliation.</p><p>j. Pruritis includes pruritus, pruritus genital.</p><p>k. Dyspnea includes dyspnea, dyspnea exertional.</p><p>l. Cough includes cough, productive cough.</p><p>m. Dizziness includes dizziness, balance disorder.</p><p>n. Hemorrhage includes anal hemorrhage, hemothorax, gastrointestinal hemorrhage, hematochezia, hematuria, hemoptysis, hemorrhage intracranial, hyphema, small intestinal hemorrhage, upper gastrointestinal hemorrhage, vaginal hemorrhage.</p><p>o. Left ventricular dysfunction/cardiomyopathy includes ejection fraction decreased, cardiac failure, cardiac failure congestive.</p><p>Other clinically important adverse reactions occurring in &lt;10% of patients who received MEKTOVI in combination with encorafenib were:</p><p>Nervous system disorders: <em>Peripheral neuropathy, Dysgeusia,</em> <em>Facial paresis</em></p><p>Gastrointestinal disorders: <em>Pancreatitis</em></p><p>Skin and subcutaneous tissue disorders: <em>Hyperkeratosis, Erythema, </em><em>Photosensitivity</em></p><p>Immune system disorders:<em> </em><em>Drug hypersensitivity</em></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="3"><p>Table&nbsp;6: Laboratory Abnormalities Occurring in &ge;10% (All Grades) of Patients Receiving MEKTOVI with Encorafenib in PHAROS<sup>a</sup></p></td></tr><tr><td rowspan="2"><p>&nbsp;</p><p>Laboratory Abnormality<sup>b</sup></p></td><td colspan="2"><p>MEKTOVI with encorafenib</p></td></tr><tr><td><p>All</p><p>Grades</p><p>(%)</p></td><td><p>Grades</p><p>3 and 4</p><p>(%)</p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p>Hematology</p></td></tr><tr><td style="vertical-align:top"><p>Anemia</p></td><td><p>47</p></td><td><p>11</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Lymphopenia</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Thrombocytopenia</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p>Leukopenia</p></td><td><p>12</p></td><td><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia</p></td><td><p>12</p></td><td><p>1.1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Chemistry</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Increased creatinine</p></td><td style="vertical-align:top"><p>91</p></td><td style="vertical-align:top"><p>3.2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Hyperglycemia</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Increased creatine kinase</p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>3.3</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Lipase increased</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>14</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Increased ALT</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Hypoalbuminemia</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Increased AST</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Increased alkaline phosphatase</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>3.2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Hyperkalemia</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>2.1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Hyponatremia</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Serum amylase increased</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Hypocalcemia</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>2.1</p></td></tr></tbody></table><p>a.&nbsp;&nbsp; Grades per National Cancer Institute CTCAE v4.03.</p><p>b.&nbsp;&nbsp; Based on the number of patients with available baseline and at least one on-treatment laboratory test.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to National Pharmacovigilance Center (NPC).</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:354px"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center (NPC)</strong></p><p>Call center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since binimetinib is 97% bound to plasma proteins, hemodialysis is likely to be ineffective in the treatment of overdose with MEKTOVI.</p><p><em>&nbsp;</em></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors, ATC code: L01EE03</p><p><strong>&nbsp;</strong></p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Binimetinib is a reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activity. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway. In vitro, binimetinib inhibited extracellular signal-related kinase (ERK) phosphorylation in cell-free assays as well as viability and MEK-dependent phosphorylation of BRAF‑mutant human melanoma cell lines. Binimetinib also inhibited in vivo ERK phosphorylation and tumor growth in BRAF-mutant murine xenograft models.</p><p>&nbsp;</p><p>Binimetinib and encorafenib target two different kinases in the RAS/RAF/MEK/ERK pathway. Compared to either drug alone, coadministration of encorafenib and binimetinib resulted in greater anti-proliferative activity in vitro in BRAF mutation-positive cell lines and greater anti-tumor activity with respect to tumor growth inhibition in BRAF V600E mutant human melanoma xenograft studies in mice. Additionally, the combination of binimetinib and encorafenib delayed the emergence of resistance in BRAF V600E mutant human melanoma xenografts in mice compared to either drug alone. In a BRAF V600E mutant NSCLC patient-derived xenograft model in mice, coadministration of encorafenib and binimetinib resulted in greater anti-tumor activity compared to binimetinib alone, with respect to tumor growth inhibition. Increased tumor growth delay after dosing cessation was also observed with the coadministration compared to either drug alone.</p><p>&nbsp;</p><p>Cardiac Electrophysiology</p><p>Following MEKTOVI 45 mg twice daily, no clinically meaningful QT prolongation was observed.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em>BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma </em></p><p>MEKTOVI in combination with encorafenib was evaluated in a randomized, active-controlled, open-label, multicenter trial (COLUMBUS; NCT01909453). Eligible patients were required to have BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, as detected using the bioMerieux THxID&trade;BRAF assay. Patients were permitted to have received immunotherapy in the adjuvant setting and one prior line of immunotherapy for unresectable locally advanced or metastatic disease. Prior use of BRAF inhibitors or MEK inhibitors was prohibited. Randomization was stratified by American Joint Committee on Cancer (AJCC) Stage (IIIB, IIIC, IVM1a or IVM1b, versus IVM1c), Eastern Cooperative Oncology Group (ECOG) performance status (0 versus 1), and prior immunotherapy for unresectable or metastatic disease (yes versus no).</p><p>&nbsp;</p><p>Patients were randomized (1:1:1) to receive MEKTOVI 45&nbsp;mg twice daily in combination with encorafenib 450 mg once daily (MEKTOVI in combination with encorafenib), encorafenib 300&nbsp;mg once daily, or vemurafenib 960 mg twice daily. Treatment continued until disease progression or unacceptable toxicity. Only the results of the approved dosing (MEKTOVI 45 mg in combination with encorafenib 450 mg) are described below.</p><p>&nbsp;</p><p>The major efficacy outcome measure was progression-free survival (PFS), as assessed by a blinded independent central review, to compare MEKTOVI in combination with encorafenib with vemurafenib. Additional efficacy measures included overall survival (OS), as well as objective response rate (ORR) and duration of response (DoR) which were assessed by central review.</p><p>&nbsp;</p><p>A total of 577 patients were randomized, 192 to the MEKTOVI in combination with encorafenib arm, 194 to the encorafenib arm, and 191 to the vemurafenib arm. Of the 383 patients randomized to either the MEKTOVI in combination with encorafenib or the vemurafenib arms, the median age was 56 years (20 to 89 years), 59% were male, 91% were White, and 72% had baseline ECOG performance status of 0. Ninety-five percent (95%) had metastatic disease, 65% were Stage IVM1c, and 4% received prior CTLA-4, PD-1, or PD-L1 directed antibodies. Twenty-eight percent (28%) had elevated baseline serum lactate dehydrogenase (LDH), 45% had &ge;3 organs with tumor involvement at baseline, and 3% had brain metastases. Based on centralized testing, 100% of patients&rsquo; tumors tested positive for BRAF mutations; BRAF V600E (88%), BRAF V600K (11%), or both (&lt;1%).&nbsp;</p><p>&nbsp;</p><p>MEKTOVI in combination with encorafenib demonstrated a statistically significant improvement in PFS compared to vemurafenib. Efficacy results are summarized in Table&nbsp;7 and Figure&nbsp;1.</p><p><em>&nbsp;</em></p><p>Table&nbsp;7: Efficacy Results for COLUMBUS</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p></td><td><p>MEKTOVI</p><p>with encorafenib<br />N=192</p></td><td><p>Vemurafenib</p><p>N=191</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Progression-Free Survival</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Number of events (%)</p></td><td style="vertical-align:top"><p>98 (51)</p></td><td style="vertical-align:top"><p>106 (55)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Progressive disease</p></td><td style="vertical-align:top"><p>88 (46)</p></td><td style="vertical-align:top"><p>104 (54)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Death</p></td><td style="vertical-align:top"><p>10 (5)</p></td><td style="vertical-align:top"><p>2 (1)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Median PFS, months (95% CI)</p></td><td style="vertical-align:top"><p>14.9 (11.0, 18.5)</p></td><td style="vertical-align:top"><p>7.3 (5.6, 8.2)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; HR (95% CI)<sup>a</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.54 (0.41, 0.71)</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp; P </em>value<sup>b</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td colspan="3"><p>Overall Survival<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Number of events (%)</p></td><td style="vertical-align:top"><p>139 (72)</p></td><td style="vertical-align:top"><p>147 (77)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Median OS, months (95% CI)</p></td><td style="vertical-align:top"><p>33.6 (24.4, 39.2)</p></td><td style="vertical-align:top"><p>16.9 (14.0, 24.5)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; HR (95% CI)<sup>a</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.67 (0.53, 0.84)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Overall Response Rate</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; ORR (95% CI)</p></td><td style="vertical-align:top"><p>63% (56%, 70%)</p></td><td style="vertical-align:top"><p>40% (33%, 48%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; CR</p></td><td style="vertical-align:top"><p>8%</p></td><td style="vertical-align:top"><p>6%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; PR</p></td><td style="vertical-align:top"><p>55%</p></td><td style="vertical-align:top"><p>35%</p></td></tr><tr><td style="vertical-align:top"><p>Duration of Response</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Median DoR, months (95% CI)</p></td><td style="vertical-align:top"><p>16.6 (12.2, 20.4)</p></td><td style="vertical-align:top"><p>12.3 (6.9, 16.9)</p></td></tr></tbody></table><p>CI = Confidence interval; CR = Complete response; DoR = Duration of response; HR = Hazard ratio; NE = Not estimable; ORR = Overall response rate; OS = Overall survival; PFS = Progression-free survival; PR = Partial response.</p><p>a.&nbsp;&nbsp; Estimated with Cox proportional hazard model adjusted by the following stratification factors: American Joint Committee on Cancer (AJCC) Stage (IIIB, IIIC, IVM1a or IVM1b, versus IVM1c) and Eastern Cooperative Oncology Group (ECOG) performance status (0 versus 1).</p><p>b.&nbsp;&nbsp; Log-rank test adjusted by the same stratification factors.</p><p>c.&nbsp;&nbsp; Based on a cutoff date 82.4 months after the date of PFS analysis.</p><p>&nbsp;</p><p>Figure&nbsp;1: Kaplan-Meier Curves for Progression-Free Survival in COLUMBUS</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_3" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:450pt;height:300pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/13/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="600" height="400" src="file:///C:/Users/bakhsm/AppData/Local/Temp/13/msohtmlclip1/01/clip_image002.jpg" /></p><p><strong>&nbsp;</strong></p><p><em>BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer</em></p><p>MEKTOVI in combination with encorafenib was evaluated in an open-label, multicenter, single‑arm study in patients with BRAF V600E mutation-positive metastatic non-small cell lung cancer (NSCLC) (PHAROS; NCT03915951). Eligible patients had a diagnosis of histologically-confirmed metastatic NSCLC with BRAF V600E mutation that was treatment-na&iuml;ve or had been previously treated with 1 prior line of systemic therapy in the metastatic setting (platinum-based chemotherapy and/or anti-PD-1/PD-L1 therapies), age 18 years or older, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1, and measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Prior use of BRAF inhibitors or MEK inhibitors was not allowed.</p><p>&nbsp;</p><p>Patients received MEKTOVI 45 mg orally twice daily and encorafenib 450 mg once daily until disease progression or unacceptable toxicity. The major efficacy outcome measures were objective response rate (ORR) per RECIST v1.1 and duration of response (DoR) as assessed by independent review committee (IRC).</p><p>&nbsp;</p><p>In the efficacy population, BRAF V600E mutation status was determined by prospective local testing using tumor tissue (78%) or blood (22%) specimens. Of the 98 patients with BRAF V600E mutation, 6 patients were enrolled into the trial based on testing of their tumor tissue specimens with the FoundationOne CDx tissue test. Of the remaining 92 patients enrolled based on local testing, 68 patients had their tumor tissue specimens retrospectively confirmed as having BRAF V600E positive status by the FoundationOne CDx tissue test. The remaining patients had either BRAF V600E negative status (n=5) or had unevaluable results (n=19) by the FoundationOne CDx tissue test. In addition, plasma samples from 81 out of 98 patients were retrospectively tested using the FoundationOne Liquid CDx assay. Of the 81 patients, 48 were confirmed positive for BRAF V600E, while 33 patients were BRAF V600E mutation negative by FoundationOne Liquid CDx assay. The remaining 17 samples had unevaluable results with FoundationOne Liquid CDx assay.</p><p>&nbsp;</p><p>The efficacy population included 59 treatment-na&iuml;ve patients and 39 previously-treated patients. Among these 98 patients, the median age was 70 years (range: 47&nbsp;to 86); 53% female; 88% White, 7% Asian, 3% Black or African American, and 1% American Indian or Alaska Native; 99% were not Hispanic or Latino; 13% were current smokers and 57% were former smokers; 73% had ECOG PS of 1; and 97% had adenocarcinoma. All patients had metastatic disease and 8% had brain metastases at baseline.</p><p>Efficacy results for patients with BRAF V600E mutation-positive metastatic NSCLC are summarized in Table 8.</p><p><strong>&nbsp;</strong></p><p><strong>Table 8: Efficacy Results for PHAROS</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:606px"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>MEKTOVI with encorafenib</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Efficacy Parameter</strong></p></td><td style="vertical-align:top"><p><strong>Treatment na&iuml;ve<br />(N=59)</strong></p></td><td style="vertical-align:top"><p><strong>Previously treated<br />(N=39)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Objective Response Rate<sup>a</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ORR (95% CI)</p></td><td style="vertical-align:top"><p>75% (62, 85)</p></td><td style="vertical-align:top"><p>46% (30, 63)</p></td></tr><tr><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>15%</p></td><td style="vertical-align:top"><p>10%</p></td></tr><tr><td style="vertical-align:top"><p>PR</p></td><td style="vertical-align:top"><p>59%</p></td><td style="vertical-align:top"><p>36%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Duration of Response<sup>a</sup></strong></p></td><td style="vertical-align:top"><p>N=44</p></td><td style="vertical-align:top"><p>N=18</p></td></tr><tr><td style="vertical-align:top"><p>Median DoR, months<br />(95% CI)</p></td><td style="vertical-align:top"><p>NE (23.1, NE)</p></td><td style="vertical-align:top"><p>16.7 (7.4, NE)</p></td></tr><tr><td style="vertical-align:top"><p>% with DoR &ge;6 months</p></td><td style="vertical-align:top"><p>75%</p></td><td style="vertical-align:top"><p>67%</p></td></tr><tr><td style="vertical-align:top"><p>% with DoR &ge;12 months</p></td><td style="vertical-align:top"><p>59%</p></td><td style="vertical-align:top"><p>33%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>CI = Confidence interval; CR = Complete response; DoR = Duration of response; N = Number of patients; NE = Not estimable; ORR = Objective response rate; PR = Partial response.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a.<strong>&nbsp;&nbsp; </strong>Assessed by Independent Central Review (ICR).</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of binimetinib was studied in healthy subjects and patients with solid tumors. After twice-daily dosing, the accumulation is 1.5-fold and the coefficient of variation (CV%) of the area under the concentration-time curve (AUC) is &lt; 40% at steady state. The systemic exposure of binimetinib is approximately dose proportional.</p><p><u>&nbsp;</u></p><p><u>Absorption</u></p><p><u>&nbsp;</u></p><p>After oral administration, at least 50% of the binimetinib dose was absorbed with a median time to maximum concentration (Tmax) of 1.6 hours.</p><p><em>&nbsp;</em></p><p><em>Effect of Food</em></p><p>The administration of a single dose of MEKTOVI 45 mg with a high-fat, high-calorie meal (consisting of approximately 150 calories from protein, 350 calories from carbohydrate, and 500 calories from fat) in healthy subjects had no effect on binimetinib exposure.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>&nbsp;</p><p>Binimetinib is 97% bound to human plasma proteins and the blood-to-plasma ratio is 0.72. The geometric mean (CV%) of apparent volume of distribution of binimetinib is 92 L (45%).</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>The mean (CV%) terminal half-life (t1/2) of binimetinib is 3.5 hours (28.5%) and apparent clearance (CL/F) is 20.2 L/h (24%).</p><p>&nbsp;</p><p><em>Metabolism</em></p><p>The primary metabolic pathway is glucuronidation with UGT1A1 contributing up to 61% of the binimetinib metabolism. Other pathways of binimetinib metabolism include N-dealkylation, amide hydrolysis, and loss of ethane-diol from the side chain. The active metabolite M3 produced by CYP1A2 and CYP2C19 represents 8.6% of the binimetinib exposure. Following a single oral dose of 45 mg radiolabeled binimetinib, approximately 60% of the circulating radioactivity AUC in plasma was attributable to binimetinib.</p><p>&nbsp;</p><p><em>Excretion</em></p><p>Following a single oral dose of 45 mg radiolabeled binimetinib in healthy subjects, 62% (32% unchanged) of the administered dose was recovered in the feces while 31% (6.5% unchanged) was recovered in the urine.</p><p><u>&nbsp;</u></p><p><u>Specific Populations</u></p><p>Age (20 to 94 years), sex, or body weight do not have a clinically important effect on the systemic exposure of binimetinib. The effect of race or ethnicity on the pharmacokinetics of binimetinib is unknown.</p><p>&nbsp;</p><p><em>Hepatic Impairment:</em> No clinically meaningful changes in binimetinib exposure (AUC and Cmax) were observed in subjects with mild hepatic impairment (total bilirubin &gt; 1 and &le; 1.5 &times; ULN and any AST or total bilirubin &le; ULN and AST &gt; ULN) as compared to subjects with normal liver function (total bilirubin &le; ULN and AST &le; ULN). A 2-fold increase in AUC was observed in subjects with moderate (total bilirubin &gt; 1.5 and &le; 3 &times; ULN and any AST) or severe (total bilirubin levels &gt; 3 &times; ULN and any AST) hepatic impairment (see section 2.4).</p><p>&nbsp;</p><p><em>Renal Impairment: </em>In subjects with severe renal impairment (eGFR &le; 29 mL/min/1.73 m2), no clinically important changes in binimetinib exposure were observed as compared to subjects with normal renal function.</p><p><u>&nbsp;</u></p><p><u>Medicinal product interactions</u></p><p><u>&nbsp;</u></p><p>Clinical Studies</p><p><em>Effect of UGT1A1 Inducers or Inhibitors on </em><em>Binimetinib</em>: UGT1A1 genotype and smoking (UGT1A1 inducer) do not have a clinically important effect on binimetinib exposure. Simulations predict similar C<sub>max</sub> of binimetinib 45 mg in the presence or absence of atazanavir 400 mg (UGT1A1 inhibitor).</p><p>No differences in binimetinib exposure have been observed when MEKTOVI is coadministered with encorafenib.</p><p><em>&nbsp;</em></p><p><em>Effect of Binimetinib on </em><em>CYP Substrates</em>: Binimetinib did not alter the exposure of a sensitive CYP3A4 substrate (midazolam).</p><p><em>&nbsp;</em></p><p><em>Effect of </em><em>Acid Reducing Agents on Binimetinib</em>: The extent of binimetinib exposure (AUC) was not altered in the presence of a gastric acid reducing agent (rabeprazole).</p><p>&nbsp;</p><p>In Vitro Studies</p><p><em>Effect of Binimetinib on CYP </em><em>Substrates:</em> Binimetinib is not a time-dependent inhibitor of CYP1A2, CYP2C9, CYP2D6 or CYP3A.</p><p><em>Effect of Transporters on Binimetinib: </em>Binimetinib is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Binimetinib is not a substrate of organic anion transporting polypeptide (OATP1B1, OATP1B3, OATP2B1) or organic cation transporter 1 (OCT1).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carcinogenicity studies with binimetinib have not been conducted. Binimetinib was not genotoxic in studies evaluating reverse mutations in bacteria, chromosomal aberrations in mammalian cells, or micronuclei in bone marrow of rats.</p><p>&nbsp;</p><p>No dedicated fertility studies have been conducted with binimetinib in animals. In general toxicology studies in rats and monkeys, there were no remarkable findings in male or female reproductive organs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>Lactose monohydrate</p><p>Cellulose microcrystalline (E460i)</p><p>Silica colloidal anhydrous (E551)</p><p>Croscarmellose sodium (E468)</p><p>Magnesium stearate&nbsp; (E470b)</p><p>&nbsp;</p><p><u>Film-coating</u></p><p>Polyvinyl alcohol (E1203)</p><p>Macrogol 3350 (E1521)</p><p>Titanium dioxide (E171)</p><p>Talc (E533b)</p><p>Iron oxide yellow (E172)</p><p>Iron oxide black (E172)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PVDC/Alu blister containing 12&nbsp;tablets. Each pack contains 84&nbsp;tablets<strong>.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER
Pfizer Europe MA EEIG 
Boulevard de la Plain 17, 1050 Bruxelles, Belgium

MANUFACTURER
ALMAC Pharma Services Limited
Portadown, Craigavon, United Kingdom

PACKAGINIG & RELEASE BY
Pierre Fabre Médicament Production Site
Progipharm, GIEN, France


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	September 2024

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>